

GENOMED4ALL

Genomics and Personalized Medicine for
all through Artificial Intelligence in
Haematological Diseases



GENOMED4ALL receives funding from the European Union's Horizon 2020
Research and Innovation programme under Grant Agreement No. 101017549

Genomics for Next Generation Healthcare

Our mission

GenoMed4All is the European initiative to transform the response to **Haematological Diseases** by seizing the power of **Artificial Intelligence**

The project represents a quantum leap in **advanced precision medicine**, pooling **genomic/ '-omics' health data** through a secure and trustworthy **Federated Learning** platform.

Our disruptive AI models, scaled up by **High-Performance Computing**, will boost the processing capacity of data repositories from **10 clinical sites** across Europe, empowering forward-thinking research of common and rare Haematological Diseases



Unleashing the power of AI

Our ambition

The massive connection of **-omics** and **clinical data** repositories across Europe offers:

More **accurate Deep Neural Networks** regression and classification models

Explicit features extraction using **advanced generative models** such as **Variational Autoencoders** and **Generative Adversarial Networks**

Optimal fusion architectures using heterogeneous data as a combination of **feedforward**, **convolutional** and **recurrent** networks

What are we aiming for?

86+

Clinical repositories with genomics data connected across 15 EU countries

15%

Accuracy improvement in specific genomic markers for prognosis and treatment

20%

Increase in the adoption of open standards for -omics data per clinical site

80%

Time reduction in AI analysis and model training through Supercomputing

An open source data hub for haematological diseases

Our principles



Innovation

Using Graph Neural Networks to distributedly train deep learning algorithms



Interoperability

Enabling collaborative, cross-border data sharing that is standard-compliant



Trust

Offering security and privacy by design in all data exchanges, model training and storage




Scalability

Using containerization to build modularity and facilitate massive replicability

Data sources


- Imaging data 
- omics data 
- Bio bank 
- Clinical trials 
- Population health 
- Other public data sources 

Registry control



Hospital control

GENOMED4ALL platform



The context for Haematological Diseases

Our challenges



Most have a genetic background

There are up to 450 variants (oncological and non-oncological) resulting from abnormalities in blood cells, lymphoid organs and coagulation factors



They represent a growing public health challenge

Haematological malignancies account for 5% of cancers, most can cause chronic health problems and many are life-threatening conditions



EU repositories are unconnected

The number of available samples for haematological disorders remains small and there are currently no centralized big data repositories

Exploring new models in genomics for precision medicine

AI-based services for clinical support

GenoMed4All will deploy 'white box' AI models in 3 real-world pilots for common and rare oncological (**Myelodysplastic syndromes** and **Multiple Myeloma**) and non-oncological (**Sickle Cell Disease**) haematological diseases



Diagnosis

AI algorithms for early identification of high-risk individuals



Prognosis

Prediction algorithms for insights on disease development



Treatment

Clinical algorithms to aid decision-making in risk stratification

Myelodysplastic syndromes

The disease

Myelodysplastic syndromes (MDS) are a group of bone marrow failure disorders that typically affect the elderly. Patients suffer from blood cytopenia (low blood cell counts), since their bone marrow is no longer able to produce enough healthy blood cells. The disease is also known as a form of blood cancer, and in some patients can evolve into acute myeloid leukemia (AML), which is usually fatal if not treated.



Validation

Prevention based on Genomic Screening

Investigate factors that influence the development of MDS, enabling early-stage identification of individuals at risk.

Omics-based Classification and Prognosis

Personalized predictive models through integration of comprehensive genomic and clinical information.

Omics-based Clinical Decision Making

AI-based algorithms to stratify the individual probability of response to specific treatments.


Drug Repurposing

Build a rationale for drug repurposing in specific subsets of MDS.

Multiple Myeloma

The disease

Multiple Myeloma (MM) is a type of bone marrow cancer originating in plasma cells, a type of white blood cell responsible for producing antibodies to fight off infections. In patients with MM, cancerous plasma cells accumulate in the bone marrow and produce abnormal proteins instead, which can lead to decreased blood cell numbers, bone and kidney damage.



Validation

Understand Disease Complexity

Describe the different layers of MM heterogeneity integrating baseline genomic and imaging data.

Identify Evolution Dynamics

Define the quantitative and qualitative dynamics of the disease in time.

Study Risk Progression

Develop a prognostic risk score for the baseline and the disease remaining after therapy.

Integrate Radiomics and Radiogenomics

Develop and validate a model to predict treatment response and determine progression-free survival.

Sickle Cell Disease

The disease

Sickle Cell Disease (SCD) is a group of hereditary red blood cell disorders. It is a rare, chronic and life-threatening disease, in which red blood cells become C-shaped in resemblance to a sickle, the farming tool the disease is named after. Sickle cells die early and tend to clog the blood flow when going through small blood vessels, so patients usually suffer from low red blood cell counts, infections, acute chest syndrome and strokes.



Validation

Identify gene mutations associated to inflammation markers

Correlations between genetic inflammatory risk profiles CRP level to develop high inflammation prediction models.

AI allocation of SCD patients to a sickling risk profile

Understand which genetic loci (GWAS) are associated with SCD patient-specific blood rheology and the point of sickling (PoS).

Develop a combined model to predict clinical outcome

Using the extent of renal damage expressed as microalbuminuria as gold standard, together with other known genetic modifiers.

AI-based Radiomics

Build a probability score using AI-based brain MRI image analysis to predict incidents of silent infarction in young SCD patients.

Meet the Team

23 organizations from 8 EU countries



ThermoFisher
SCIENTIFIC



Datawizard



HUMANITAS
RESEARCH HOSPITAL



ASSISTANCE PUBLIQUE  HÔPITAL DE PARIS



ESIEE
PARIS

CINECA



GENOMED
4ALL

Visit us!

genomed4all.eu



@genomed4all



/genomed4all